Detalhe da pesquisa
1.
Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial.
J Infect Dis;
228(3): 299-310, 2023 08 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36722147
Mostrar mais
Texto completo
Documentos relacionados
2.
Demographic diversity of US-based participants in GSK-sponsored interventional clinical trials.
Clin Trials;
20(2): 133-144, 2023 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36744680
3.
Adverse infant outcomes following low-risk pregnancies in England: a retrospective cohort study.
BMC Pregnancy Childbirth;
23(1): 330, 2023 May 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37161382
4.
Three Dose Levels of a Maternal Respiratory Syncytial Virus Vaccine Candidate Are Well Tolerated and Immunogenic in a Randomized Trial in Nonpregnant Women.
J Infect Dis;
225(12): 2067-2076, 2022 06 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34146100
5.
Facilitating safety evaluation in maternal immunization trials: a retrospective cohort study to assess pregnancy outcomes and events of interest in low-risk pregnancies in England.
BMC Pregnancy Childbirth;
22(1): 461, 2022 Jun 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35650569
6.
Association of Group B Streptococcus (GBS) Serum Serotype-Specific Anticapsular Immunoglobulin G Concentration and Risk Reduction for Invasive GBS Disease in South African Infants: An Observational Birth-Cohort, Matched Case-Control Study.
Clin Infect Dis;
73(5): e1170-e1180, 2021 09 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33341870
7.
Safety and Immunogenicity of a Second Dose of an Investigational Maternal Trivalent Group B Streptococcus Vaccine in Nonpregnant Women 4-6 Years After a First Dose: Results From a Phase 2 Trial.
Clin Infect Dis;
70(12): 2570-2579, 2020 06 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31394574
8.
Safety and immunogenicity of a varicella vaccine without human serum albumin (HSA) versus a HSA-containing formulation administered in the second year of life: a phase III, double-blind, randomized study.
BMC Pediatr;
19(1): 50, 2019 02 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30732648
9.
Incidence of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Illness in Infants in Low- and Middle-Income Regions During the Coronavirus Disease 2019 Pandemic.
Open Forum Infect Dis;
10(12): ofad553, 2023 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38088983
10.
Correlation of protection against varicella in a randomized Phase III varicella-containing vaccine efficacy trial in healthy infants.
Vaccine;
39(25): 3445-3454, 2021 06 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33736915
11.
Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in pregnant women and their infants: Results from a randomized placebo-controlled phase II trial.
Vaccine;
38(44): 6930-6940, 2020 10 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32883555
12.
Safety and immunogenicity of fully liquid and lyophilized formulations of an investigational trivalent group B streptococcus vaccine in healthy non-pregnant women: Results from a randomized comparative phase II trial.
Vaccine;
38(16): 3227-3234, 2020 04 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32169390
13.
Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study.
J Pediatric Infect Dis Soc;
9(2): 194-201, 2020 Apr 30.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30849175
14.
Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: 10-year follow-up of a phase 3 multicentre, observer-blind, randomised, controlled trial.
Lancet Infect Dis;
19(3): 287-297, 2019 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30765242
15.
Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: A phase III, randomized study.
Hum Vaccin Immunother;
14(11): 2624-2631, 2018.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29902133
16.
One or two doses of live varicella virus-containing vaccines: Efficacy, persistence of immune responses, and safety six years after administration in healthy children during their second year of life.
Vaccine;
36(3): 381-387, 2018 01 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29224964
17.
Pain caused by measles, mumps, and rubella vaccines: A systematic literature review.
Vaccine;
35(42): 5551-5558, 2017 10 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28893478
18.
Two-year antibody persistence in children vaccinated at 12-15 months with a measles-mumps-rubella virus vaccine without human serum albumin.
Hum Vaccin Immunother;
13(7): 1516-1522, 2017 07 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28481690
19.
The immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine when co-administered with conjugated meningococcal C vaccine to healthy children: A phase IIIb, randomized, multi-center study in Italy.
Vaccine;
34(36): 4278-84, 2016 08 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27423382
20.
Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9â months of age: a phase III, randomised, non-inferiority trial.
BMJ Open;
5(9): e007202, 2015 Sep 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26362659